Filing Details

Accession Number:
0001209191-22-021311
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-28 16:15:30
Reporting Period:
2022-03-24
Accepted Time:
2022-03-28 16:15:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1538210 Neximmune Inc. NEXI Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1843817 Grant Verstandig C/O Neximmune, Inc.
9119 Gaither Road
Gaithersburg MD 20877
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-03-24 39,995 $3.35 754,890 No 4 P Direct
Common Stock Acquisiton 2022-03-25 131,622 $4.14 886,512 No 4 P Direct
Common Stock Acquisiton 2022-03-28 18,983 $3.76 905,495 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
Footnotes
  1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.02 to $3.50, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
  2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.56 to $4.30, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
  3. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.57 to $3.98, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.